Adrenomed AG. (7/12/22). "Press Release: Adrenomed Appoints David Germonpré as Chief Financial Officer". Zurich.

	Organisation	Adrenomed AG
	Organisation 2	MTIP MedTech Innovation Partners AG
	Today	MTIP AG
	Group	MTIP (Group)
	Product	Adrecizumab
	Product 2	drug development
	Person	Germonpré, David (Adrenomed 202207– CFO before MTIP + Gemma Frisius Fund + Advisor to Govt of Flandes + Dexia Bank)
	Person 2	Jones, Richard (Adrenomed 202203– CEO before Fusion Antibodies formerly Novartis + GSK + Genzyme + Shire)

Adrenomed AG, the vascular integrity company, today announced the appointment of David Germonpré as Chief Financial Officer (CFO) of Adrenomed, effective July 11, 2022. David Germonpré has over 15 years experience as finance leader and strategist. He was instrumental in funding and developing many healthcare companies in the capacity of venture capital investor and board member.

Dr. Richard Jones, CEO of Adrenomed, said: “I am delighted to welcome David Germonpré as Adrenomed’s new Chief Financial Officer. He brings a wealth of experience, including leading financial transactions, financial management and implementing corporate and financial strategies. David will be an invaluable addition to our executive management team, and we will benefit from his in-depth understanding in managing financing rounds and M&A transactions. David brings deep operational experience and a broad network to create substantial value for Adrenomed.”

David Germonpré, CFO of Adrenomed, added: “I am excited to be joining the Adrenomed team at this important stage of scientific and corporate growth. Adrenomed has developed a differentiated biomarker-guided therapeutic approach to tackle complex disease mechanisms such as sepsis and septic shock. After a successful Phase II clinical trial, we plan to implement a pivotal clinical development program in Europe and the USA. We are determined to obtain market approval for Adrecizumab and to realize a massive breakthrough in an indication that is currently one of the most frequent causes of death in the hospital setting.”

Before joining Adrenomed, David Germonpré was Partner at MTIP, a Switzerland-based health-tech growth capital investor, where he co-led the investment team and was responsible for fundraising, deal sourcing, due diligence, deal execution and active portfolio management. Previously, for the Gemma Frisius Fund he invested in spinouts from Belgium’s KU Leuven, one of Europe’s most innovative universities. Between 2009 and 2013 David advised the Government of Flanders on venture capital and private equity programs. Prior to that he worked as an investment banker at Dexia Bank, executing M&As and IPOs of big corporates. David Germonpré obtained a master’s degree in Business Administration from Ghent University, Belgium. In 2013 he completed an Executive MBA at the IE Business School in Madrid, Spain.

About Adrenomed

Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company. Adrenomed’s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of in-depth experience in sepsis and deep knowledge in diagnostics and drug development, the company’s lead product candidate Adrecizumab (INN: enibarcimab) is a first-in-class non-blocking monoclonal antibody. Adrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Adrecizumab has successfully completed a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II trial with 301 patients suffering from septic shock. For further information, please visit www.adrenomed.com and follow us on LinkedIn and Twitter.

Contact

Adrenomed AG
Martina Kalle-Brune, Ph.D.
phone: +49 (0)3302 207780
[email protected]

Media Inquiries
MC Services AG
Eva Bauer / Julia von Hummel
phone: +49 (0)89 2102280
[email protected]

Record changed: 2024-12-28